Table 1.
Demographic and clinical characteristics in mild to moderate patients with SARS-CoV-2 Omicron based on neurological manifestations.
|
n (%) or mean (SD) or median[IQR] |
p- value | Multivariate regressiona |
||||
|---|---|---|---|---|---|---|
| Total |
With neurological manifestations |
Without neurological manifestations |
B (95 %CI) | p-value | ||
| (n=351) | (n=169) | (n=182) | ||||
| Characteristics | ||||||
| Age, y | 70.6(15.1) | 67.4(15.7) | 73.7(14.0) | ＜0.001*** | -0.026(0.959, 0.989) | 0.001** |
| Gender | ||||||
| Female | 192(54.7) | 103(60.9) | 89(48.9) | 0.025* | 0.498(1.060, 2.555) | 0.026* |
| Male | 159(45.3) | 66(39.1) | 93(51.1) | |||
| BMI | 23.1(3.4) | 22.9(3.4) | 23.2(3.4) | 0.673 | ||
| BMI＞24 | 126(36.8) | 59(34.9) | 67(38.7) | 0.587 | ||
| Comorbidities | ||||||
| Any | 291(84.6) | 130(76.9) | 161(88.5) | 0.005** | -0.420(0.320, 1.350) | 0.253 |
| Hypertension | 186(53.0) | 91(53.8) | 95(52.2) | 0.831 | ||
| Diabetes | 67(19.1) | 25(14.8) | 42(23.1) | 0.057 | -0.286(0.405, 1.396) | 0.366 |
| Cardiac disease | 109(31.1) | 53(31.4) | 56(30.8) | 0.909 | ||
| Cerebrovascular disease | 73(20.8) | 36(21.3) | 37(20.3) | 0.895 | ||
| Chronic lung disease | 51(14.5) | 30(17.8) | 21(11.5) | 0.129 | ||
| Comorbidities ≥ 2 | 201(57.3) | 88(52.1) | 113(62.1) | 0.067 | 0.168(0.677, 2.068) | 0.554 |
| Vaccinated | 141(40.2) | 79(46.7) | 62(34.1) | 0.017* | 0.277(0.721, 2.413) | 0.369 |
| Booster injection | 77(22.1) | 46(27.4) | 31(17.1) | 0.028* | -0.180(0.414, 1.685) | 0.615 |
| Degree of severity | ||||||
| Mild | 286(81.5) | 132(78.1) | 154(84.6) | 0.131 | ||
| Moderate | 65(18.5) | 37(21.9) | 28(15.4) | |||
| Treatment | ||||||
| Traditional Chinese Medicine | 328(93.4) | 161(95.3) | 167(91.8) | 0.202 | ||
| Antibiotics | 78(22.3) | 38(22.5) | 40(22.1) | 1.000 | ||
| Anticoagulation | 59(16.9) | 19(11.2) | 40(22.2) | 0.007** | 0.634(0.288, 0.978) | 0.042* |
| Glucocorticoid | 27(7.7) | 9(5.3) | 18(10.0) | 0.113 | ||
| Thymosin | 73(20.9) | 32(18.9) | 41(22.7) | 0.431 | ||
| Paxlovid | 221(63.0) | 100(59.2) | 121(66.5) | 0.184 | ||
| Nutritional support | 106(30.2) | 42(24.9) | 64(35.2) | 0.037* | -0.141(0.514, 1.465) | 0.597 |
| Clinical outcomes | ||||||
| Onset of positive to negative, d | 9(7, 12,3) | 9(7, 13) | 9(7, 12) | 0.381 | ||
| Onset of treatment to negative, d | 6(2, 8) | 6(2, 8) | 6(3, 8) | 0.364 | ||
| Length of hospitalization, d | 8(5, 11) | 8.5(5, 11) | 8(5, 11) | 0.752 | ||
| Follow-up | ||||||
| Residual abnormalities | 25(7.1) | 16(9.5) | 9(4.9) | 0.145 | ||
Abbreviation: BMI, body mass index; y, year; d, day.
Note：*, p < 0.05; **, p < 0.01; ***, p < 0.001; a, Significant variables(p < 0.1) from univariate analyses(comorbidities, diabetes, vaccinated, booster injection, anticoagulation and nutritional support) were entered into the logistic regression analysis model.